Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

endpoint was based on an intent-to-treat (ITT) analysis, which included all patients randomized in the study. However, three patients did not receive study drug but were included in the analysis as nonresponders. In the primary analysis of the combined group of patients receiving either golimumab 50 mg or 100 mg in combination with MTX, 38 percent (40 percent receiving 50 mg and 37 percent receiving 100 mg) achieved at least 50 percent improvement in signs and symptoms of RA (ACR 50) through week 24, compared with 29 percent of patients receiving placebo plus MTX (p=0.053 for the combined group, p=0.042 for 50 mg and p=0.177 for 100 mg). When the three patients who did not receive golimumab were excluded in a modified intent-to-treat (mITT) analysis, the results showed that 39 percent of patients in the combined golimumab plus MTX group (41 percent receiving 50 mg and 37 percent receiving 100 mg) achieved ACR 50, compared with 29 percent of patients receiving placebo plus MTX (p=0.049 for the combined group, p=0.038 for 50 mg and p=0.177 for 100 mg). Additionally, 62 percent of patients in the combined golimumab plus MTX group (62 percent for each dose group) achieved ACR 20, compared with 49 percent receiving placebo plus MTX (p=0.011 for the combined group and p=0.028 for each dose group).

"These data show that treatment with golimumab induces an important depth of response, improving multiple aspects of rheumatoid arthritis and leading to significant decreases in disease activity," said Roy Fleischmann, M.D., Clinical Professor, Department of Internal Medicine at the University of Texas Southwestern Medical Center; Chief, Division of Rheumatology at St. Paul University Hospital in Dallas, Texas and lead study investigator. "Golimumab, which is an anti-TNF therapy, is a promising treatment option for multiple patient populations with this chronic and potentially debilitating inflammatory disease."

Also at week 24, patients receiving golimumab plus MT
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... luglio 2014 ResMed (NYSE: RMD ... la cura dei disturbi respiratori del sonno (SDB) e ... permanente in Germania contro il produttore Taiwanese di dispositivi ... di apparecchiature da indossare in testa, che violano i ... 220. La sentenza della Corte Regionale Distrettuale di ...
(Date:7/28/2014)... OXFORD, England , July 28, 2014 ... bekannt, dass Albion Ventures 2,5 Millionen £ ... Kundenautomatisierungsmanagement in der Konsumgüter-, Gesundheits-, Pharma- und ... Shackleton Ventures.      (Photo: ... letzten 18 Monaten hat OmPrompt sein beschleunigtes ...
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
Breaking Medicine Technology:ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2
... 2012  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c ... loss from continuing operations of $513,000, or $0.16 per ... compared to income from continuing operations of $909,000, or ...
... OAKS, Calif., May 4, 2012  Amgen (NASDAQ: AMGN ... Wednesday, May 9, 2012, at the Four Seasons Hotel, Chicago, ... vice president of Investor Relations at Amgen, will present. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 2Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 3Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 4Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 5Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 6Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 7Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 8
(Date:7/28/2014)... CA (PRWEB) July 28, 2014 At some ... uncomfortable situation where they’re forced to contact the authorities. ... more difficult than it initially seems. , Not every dangerous ... vehicle get stolen, a person get mugged, or a bank ... less obvious, leading onlookers to be more passive than they ...
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types (Carbohydrase, ... Bio-Fuel, Animal Feed), & Geography - Global Trends ... global industrial enzymes market with analysis and forecasting ... also identifies driving and restraining factors for the ... opportunities, burning issues, winning imperatives, and challenges. The ...
(Date:7/28/2014)... July 28, 2014 "Fist bumping" transmits significantly ... still addressing the cultural expectation of hand-to-hand contact ... published in the August issue of the ... publication of the Association for Professionals in Infection ... from the Institute of Biological, Environmental, and Rural ...
(Date:7/28/2014)... Qualis Health, one of the ... has published a complimentary, online toolkit that provides ... and families in infection control. Tested and ... toolkit provides a step-by-step roadmap for implementing an ... families early in a hospital stay. , “Across ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Recent research ... desk all day for years can lead to a ... cardiovascular disease. But using a standing desk, or an ... pain, often driving office workers back to a seated ... are designed to alleviate this leg pain and ...
Breaking Medicine News(10 mins):Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:New Standing Desk Anti-fatigue Mats from Martinson-Nicholls Reduce Leg Fatigue and Discomfort Working at Standing and Sit-to-Stand Desks 2
... brain may have problems in forming perception categories for// printed ... to the dyslexics finding it difficult to filter out visual ... of them. ,The research by the scientists from University ... the nature of the workings of a dyslexic brain. ...
... to lose knee lubrication following an injury to the knee. ... University of Rhode Island had identified a way to find ... knee after a knee injury, in order to find out ... ,Although knee injury is considered to be a risk ...
... that children are more exposed to indoor allergens// at ... that are commonly found indoor include bacteria, molds, mildew, ... cockroaches and pollens. These may cause allergic reactions like ... Some of the symptoms experienced by people in presence ...
... survived cancer may have higher risks of having cognitive// ... University of Southern California had found that patients who ... twice as much risk as their healthy counterparts of ... survivors of cancer and their twins with the help ...
... Canada helped in conceiving and// delivering world’s first baby ... mother of the baby had her eggs collected from ... thawed and fertilized from sperms of her partner through ... was implanted in her uterus, which she carried to ...
... constantly exposed to air pollutions of big// cities may ... ,Inhalation of polluted air of the metros can ... particles emitted from the cars, trucks, buses, tobacco smoke, ... the chromosome of the fetus. , ,The research ...
Cached Medicine News:
... I Direct to High Res SSP kits provide high ... tray. Locus specific typing on a single tray reduces ... Straight from genomic DNA to high resolution results, no ... typing with a single tray , Unique reaction pattern ...
... built-in bags as in a suspension file system, ... contacting the ethylene glycol and without having to ... easy handling and maximum surface freezing concurrently with ... relatively hot air under the lid does not ...
... 8624 is UL Listed, CSA ... Plasma Freezers safely store single ... cryoprecipitate. Recorders are standard. Cold ... (12.7cm) of foamed-inplace polyurethane insulation ...
... A small self-contained freezer complying with ... blood plasma. External finish is grey colorbond ... assisted lid opening to a 40-litre capacity ... an effective single gasket contacting a heated ...
Medicine Products: